Therapeutic adherence in adults with type 2 diabetes in a chronic disease program. Huánuco 2017

  • Giannina Acuña-Carbajal Universidad Nacional Hermilio Valdizán, Huánuco, Perú
  • Carlos A. Huamancayo-Inga Universidad Nacional Hermilio Valdizán, Huánuco, Perú
  • German Guisasola Hospital II EsSalud – Huánuco
Keywords: adherence to treatment, type 2 diabetes, family dysfunction, knowledge


Objective: To assess whether knowledge about Diabetes Mellitus (DM), family functionality and depression are associated with Therapeutic Adherence in adults with type 2 DM.

Methods: Analytical study of cross section. It was carried out in the diabetes program of CAP-UNHEVAL of Hospital II Essalud. Participants: patients with type 2 DM. Interventions: According to the inclusion and exclusion criteria. Validated collection instruments were used, interviewed for two months. The descriptive analysis was carried out; for inferential analysis: Chi2 test with 95% significance. The statistical package SPSS and Microsoft Excel was used.

Results. The average age: 61.95 years, most frequent diseases: dyslipidemia (23.8%) and hypertension (43.6%). Knowledge about DM2 was not acceptable (86%), 95.9% with poor family function and 90.2% with depression were obtained. Variables associated with poor adherence to diabetic treatment were: family dysfunction [p = 0.00; RP = 26.18; CI: 95% (8.71 - 78.64)], unacceptable knowledge on DM2 [p = 0.00; RP= 23.57; 95% CI (8.54-65.06)] and depression [p = 0.00; RP= 6.81; 95% CI (3.00 - 15.45)].

Conclusions: Poor adherence to treatment is influenced by family dysfunction, poor knowledge about diabetes and depression.


Download data is not yet available.


Declaración Política de la Reunión de Alto Nivel de la Asamblea General sobre la Prevención y el Control de las Enfermedades No Transmisibles. En: Sexagésimo sexto período de sesiones de la Asamblea General de las Naciones Unidas. Nueva York: Naciones Unidas; 2011.

Informe Mundial Sobre La Diabetes. Organización Mundial De La Salud. Ginebra. 2016.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4*4 million participants. Lancet. 2016 Apr 9;387(10027):1513-1530.

Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: A global systematic review. PharmacoEconomics. 2015; 33(8): 811–31.

Seclén S, Rosas M, Arias A. PERUDIAB. Cohorte Peruana de Diabetes, Obesidad y Estilos de Vida en el Perú. Laboratorio Farmacéutico SANOFI.2011-2012.

Análisis De Situación De Salud. Dirección Regional de Salud. Huánuco; 2016.

World Health Organization. Adherence to long-term therapies: Evidence for action. Ginebra: WHO; 2003.

Iglay K, Cartier SE, Rosen VM, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31(7):1283-1296.

Egede LE, Gebregziabher M, Echols C, et al. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother. 2014;48(5):562-570

Domingo Orozco-Beltrán D, Mata-Cases M, Artola S, et al. Abordaje de la adherencia en diabetes mellitus tipo 2: situación actual y propuesta de posibles soluciones. Documento De Consenso. Aten Primaria. 2016; 48(6):406-420.

Connor P, Schmittdiel J, Pathak R, Harris R, Newton K, Ohnsorg K, et al. Randomized Trial of Telephone Outreach to Improve Medication Adherence and Metabolic Control in Adults with Diabetes. Diabetes Care. 2014; 37 (12): 3317-24.

Ostini R y Kairuz T. Investigating the association between health literacy and non-adherence. Int J Clin Pharm. 2014; 36(1):36-44.

Antoine L, Pieper D, Mathes T, Eikermann M. Improving the adherence of type 2 diabetes mellitus patients with pharmacy care: a systematic review of randomized controlled trials. BMC Endocr Disord. 2014;7(14):53-61.

Troncoso C, Delgado D, Rubilar C. Adherencia al tratamiento en pacientes con diabetes tipo 2. Rev Costarr Salud Pública. 2013; 22(1): 9- 13.

Gigoux J, Moya P, Silva J. Adherencia al tratamiento farmacológico y relación con el control metabólico en pacientes con DM2. Rev Chil Salud Pública. 2010; 14 (2-3): 238-70.

De Oliveira-Filho A, Morisky D, Neves S, Costa F, de Lyra D. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm. 2014 May-Jun;10(3):554-61.

Guamuro J, Vásquez G, Barrera H, Cruz L, Caceres, V. Nivel De Adherencia Al Tratamiento Farmacológico Y Dietético En Pacientes Del Programa De Diabetes Del Policlínico Chiclayo Oeste - Essalud En Diciembre Del 2015. Rev Exp Med 2016; 2(1): 23-28.

Pérez Rodríguez A, Berenguer Gouarnaluses M. Algunas consideraciones sobre la diabetes mellitus y su control en el nivel primario de salud. MEDISAN .2014 [citado 20 mar 2015]; 19(3):374-389. Disponible en:

Golberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR ,et al.Exercise and type 2 diabetes. Diabetes Care. 2010[citado 20 mar 2015]; 33(12):2692-2696. Disponible en:

How to Cite
Acuña-Carbajal G, Huamancayo-Inga C, Guisasola G. Therapeutic adherence in adults with type 2 diabetes in a chronic disease program. Huánuco 2017. Rev. Peru. Investig. Salud. [Internet]. 17Oct.2019 [cited 12Aug.2020];3(4):174-9. Available from:
Artículos originales